The Role of Pharmacotherapy in the Treatment of Adolescent Substance Use Disorders
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Summary Adolescent substance use disorders (SUDs) are associated with elevated morbidity and mortality, and represent a significant public health cost. While psychosocial interventions for adolescent SUDs have demonstrated short-term efficacy, many youth relapse after treatment. A potential approach to improve treatment response is to use adjunctive pharmacotherapy. An increasing number of medications have been shown to improve SUD treatment outcomes for alcohol, tobacco, and opioid use disorders in adults. Although relatively few randomized controlled medication trials have been conducted in adolescents, results suggest that pharmacotherapies when added to psychosocial interventions may hold similar promise for improving outcomes for adolescents with SUDs. This article provides a review of current research on the safety and efficacy of pharmacotherapies used in the treatment of adolescent SUDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why do many psychiatric disorders emerge during adolescence?
Paus, T., Keshavan, M., & Giedd, J. N. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2513 · Cited by 3,123 · cited 1×
“Neurotransmitter systems, including dopaminergic, serotonergic, noradrenergic, gamma-aminobutyric acid (GABA)ergic, and glutamatergic systems, mature across adolescence.(35,36) These developmental changes affect biochemical and phys-”
BackgroundMental Health Surveillance Among Children — United States, 2013–2019
Bitsko, R. H., Claussen, A. H., Lichstein, J., Black, L. I., Jones, S. E., Danielson, M. L., Hoenig, J. M., Davis Jack, S. P., Brody, D. J., Gyawali, S., et al. (2022) · MMWR Supplements · doi:10.15585/mmwr.su7102a1 · Cited by 1,723
Neurodevelopmental Trajectories of the Human Cerebral Cortex
Shaw, P., Kabani, N. J., Lerch, J. P., Eckstrand, K., Lenroot, R., Gogtay, N., Greenstein, D., Clasen, L., Evans, A., Rapoport, J. L., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5309-07.2008 · Cited by 1,644 · cited 1×
“Neurotransmitter systems, including dopaminergic, serotonergic, noradrenergic, gamma-aminobutyric acid (GABA)ergic, and glutamatergic systems, mature across adolescence.(35,36) These developmental changes affect biochemical and phys-”
BackgroundNeonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Wagner, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00367-0 · Cited by 739 · cited 1×
“development of SUDs peaks during adolescence and young adulthood, and decreases throughout the rest of the lifespan.(5,6) SUDs represent a major source of morbidity and mortality in the teenage years.”
BackgroundClinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review
Deepmala, Slattery, J., Kumar, N., Delhey, L., Berk, M., Dean, O., Spielholz, C., & Frye, R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.015 · Cited by 463
Mayo-Smith, M. F. (1997) · JAMA · doi:10.1001/jama.278.2.144 · Cited by 434
Evidence-Based Psychosocial Treatments for Adolescent Substance Abuse
Waldron, H. B., & Turner, C. W. (2008) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374410701820133 · Cited by 418
A Double-Blind Randomized Controlled Trial of N -Acetylcysteine in Cannabis-Dependent Adolescents
Gray, K. M., Carpenter, M. J., Baker, N. L., DeSantis, S. M., Kryway, E., Hartwell, K. J., McRae-Clark, A. L., & Brady, K. T. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010055 · Cited by 306
Lisdahl, K. M., Gilbart, E. R., Wright, N. E., & Shollenbarger, S. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00053 · Cited by 284
Cited by
Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Krist, A. H., Davidson, K. W., Mangione, C. M., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Donahue, K., Doubeni, C. A., et al. (2020) · JAMA · doi:10.1001/jama.2020.8020 · Cited by 266
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“Of note, NAC is currently being tested in adolescent AUD, a unique prospect as no other AUD pharmacotherapies are yet approved for adolescents [225].”
BackgroundNock, N. L., Minnes, S., & Alberts, J. L. (2017) · Birth Defects Research · doi:10.1002/bdr2.1182 · Cited by 61
“No medications are currently FDA indicated for cannabis use disorder (Hammond, 2016), but the efficacy of N-acetylcysteine (NAC) compared to placebo has been shown in one trial of cannabis dependent adolescents (Gray et al., 2012).”
BackgroundInfluentialAddressing Adolescents’ and Young Adults’ Substance Use Disorders
Chadi, N., Bagley, S. M., & Hadland, S. E. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.02.015 · Cited by 44
Liegner, K. B. (2019) · Antibiotics · doi:10.3390/antibiotics8020072 · Cited by 35
Metadata
- Authors
- Hammond, C. J.
- Venue
- Child and Adolescent Psychiatric Clinics of North America
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 25
- Issue
- 4
- Pages
- 685-711
- ISSN
- 1056-4993 (ISSN-L)
- OpenAlex
- W2486855689
- Cited by
- 38
- References
- 17
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.